Physician profile
Ajit Arora
NPI 1538253190
$6,722.63
in general payments reported to CMS, 2019-2025
31 companies · $2,448 in 2025
The $2,448 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $131 · 2021: $289 · 2022: $370 · 2023: $1,123 · 2024: $1,916 · 2025: $2,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,730 · Travel and Lodging: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,730.13 |
| Travel and Lodging | $756.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,865.96 | 2019-2025 | General - Therapies, Overstitch Endoscopic Suturing System, Exalt Model D |
| Abbvie INC. | $1,420.87 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Aimmune Therapeutics, INC. | $578.33 | 2024-2025 | Vowst |
| Gilead Sciences, INC. | $538.05 | 2019-2025 | Vemlidy, Livdelzi |
| Janssen Biotech, INC. | $289.88 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.15 | 2023-2024 | Xifaxan |
| Celgene Corporation | $246.29 | 2022-2023 | Zeposia |
| Pfizer INC. | $212.47 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $194.73 | 2024-2025 | Bylvay, Iqirvo |
| Madrigal Pharmaceuticals | $162.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $122.08 | 2024 | |
| Ironwood Pharmaceuticals, INC | $75.43 | 2020-2024 | |
| Ferring Pharmaceuticals INC. | $64.34 | 2019-2023 | Rebyota |
| Ardelyx, INC. | $56.18 | 2024-2025 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $51.40 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $45.71 | 2020-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $45.65 | 2019-2024 | Entyvio |
| Allergan, INC. | $44.41 | 2019 | |
| Olympus America INC. | $38.87 | 2023 | Evis Exera III Xenon Light Source |
| Genzyme Corporation | $34.37 | 2025 | |
| Shire North American Group INC | $33.95 | 2019 | |
| Celltrion USA INC. | $33.70 | 2024 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $31.75 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $29.04 | 2023 | Dificid |
| Micro-Tech Endoscopy USA, INC. | $24.79 | 2023-2025 | Riteclip, Lockado |
| Daiichi Sankyo INC. | $23.48 | 2022 | |
| Lilly USA, LLC | $22.19 | 2025 | Omvoh |
| Ultragenyx Pharmaceutical INC. | $21.63 | 2023 | |
| Novo Nordisk INC | $20.07 | 2025 | Wegovy |
| Shionogi INC | $15.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajit Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.